Here is why Pfizer can't seem to get off the mat and whether it's worth buying the dip on today. I won't rehash Pfizer's pandemic journey too much. The company developed and sold a vaccine (Comirnaty) ...

CEFs remain an attractive investment class that covers various asset classes and promises high distributions and reasonable ...

Provident Financial Services shows strong loan growth potential, stable margins, and a 5.8% yield despite market headwinds.

Second, Pfizer's forward dividend yield stands at 7.47%. At first glance, the drugmaker's dividend payout ratio of 122.5% ...

Pfizer (NYSE:PFE) recently presented groundbreaking findings in cancer research, particularly the first-in-human Phase 1 clinical study of the innovative MesoC2 drug at the ASCO Annual Meeting, and ...